Table 2 Dose-reducing index (DRI) analysis of NV1066 and PD98059 combination in HCC1937 cells

From: Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer

Fa

NV1066 (MOI)

PD98059 (mM)

DRI NV1066

DRI PD98059

0.25

0.61

176

2.23

5.15

0.5

2.26

543

2.65

5.09

0.75

8.36

167

3.14

5.03

0.95

75.2

111

4.18

4.93

  1. DRI represents the fold-change of dose reduction that would result from using each drug in combination for a given degree of effects as compared with the dose of each drug alone.26 Fraction-affected (Fa) denotes fraction affected (i.e., Fa of 0.5 is equivalent to a 50% reduction of cell growth).
Back to article page